TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02271269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value Pricing Subsidies
Description: * Usual care for glaucoma~* Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~* Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points.
Study: NCT00828776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodic - Cristália
Description: 5000UI/mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin - Liquemine (Roche)
Description: 5000UI/mL
Study: NCT03829228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proglucamune
Description: Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained \~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
Study: NCT03888443

Intervention type: DEVICE
Intervention: Bimanual 3D Motion Analysis  Be-API 
Description: Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip).

Intervention type: DEVICE
Intervention: Bimanual 3D Motion Analysis  Be-API 
Description: Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip).

Intervention type: DEVICE
Intervention: Bimanual 3D Motion Analysis  Be-API 
Description: Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip).
Study: NCT00207077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Erlotinib
Description: IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
Study: NCT04866784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic intervention for acute and chronic pain. This treatment involves the application of electric current through the skin; it is safe, easy to use, and inexpensive
Study: NCT02844569

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft bone substitute
Description: Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenograft bone substitute
Description: Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen dressing
Description: Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-collagen matrix
Description: Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
Study: NCT03925012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Study: NCT03928184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: Healthcare professional-administered intra-articular injection; performed on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthcare professional-administered intra-articular injection; performed on Day 1
Study: NCT03519035

Intervention type: OTHER
Intervention: To pass different questionnaires
Description: Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
Study: NCT01590719

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb)
Description: Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid
Description: Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinic acid
Description: If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofolinic acid
Description: If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
Study: NCT00918255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection using prefilled syringe containing 0.8 milliliters
Study: NCT02360254

Intervention type: DRUG
Intervention: Insulin degludec
Description: Once daily injection of insulin degludec
Study: NCT04670302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tendon repair procedure
Description: Tendon repair procedure:~1. Single senior surgeon (HS) will perform mini-open surgery to decompress the acromioplasty and repair the supraspinatus tendon.~2. Splicing is achieved by installing screw-type anchors on the insertional footprint of the humeral head greater tuberosity.~3. Then, double suturing of the supraspinatus tendon is performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tendon repair augmented with AAdMSC-HAM composite
Description: After double suturing of the supraspinatus tendon, the composite comprising freeze-dried HAM (2 cm x 2 cm x 0.002 cm) and AAdMSC (20 million cells) is placed on the upper surface of the splice and fixed with stitches at all four corners.
Study: NCT02678026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Description: Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
Study: NCT03925090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+Toripalimab
Description: chemotherapy and monoclonal antibody
Study: NCT01632982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: the standard drug counseling offered to patients at the study site's methadone maintenance program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: the standard drug counseling offered to patients at the study site's methadone maintenance program

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: standard treatment
Description: the standard drug counseling offered to patients at the study site's methadone maintenance program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTS (Mobile Therapeutic System)
Description: a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile control
Description: a mobile phone-based application that directs participants to the NIDA website's homepage
Study: NCT04067648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Injection
Description: three doses of sufentanil was intravenously given during anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Injection
Description: three doses of sufentanil was intravenously given during anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Injection
Description: three doses of sufentanil was intravenously given during anesthesia induction
Study: NCT01354561

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Respiratory physical therapy
Description: Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory physical therapy
Description: Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
Study: NCT04504604

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FoundationOne CDx and FoundationOne Liquid CDx
Description: Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
Study: NCT03925090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin+placebo
Description: chemotherapy
Study: NCT00941213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound scissors - Harmonic ACE
Description: preparation with ultrasound scissors during operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroscalpel (Erbe Vio 300; Aesculap AG)
Description: preparation with electroscalpel during operation
Study: NCT02279914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 mcg 3 hours prior to procedure
Description: Misoprostol 400 mcg 3 hours prior to D\&E procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 mcg 90 minutes prior to procedure
Description: Misoprostol 600 mcg 90 minutes prior to D\&E procedure
Study: NCT02092610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Implant BI300
Description: The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implant BI300
Description: The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
Study: NCT04144608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
Study: NCT01074502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apremilast
Description: apremilast 20 mgs orally twice a day for 12 weeks
Study: NCT03651479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real boxing training
Description: In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual boxing training
Description: In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
Study: NCT03410277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental hypoglycemia
Description: Experimental hypoglycemia with and without MRI
Study: NCT05132023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin & Metformin (Test)
Description: one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin & Metformin (Reference)
Description: one tablet administrated according to a randomization scheme with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 min for up to 4 hours after dosing.
Study: NCT00896077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisofylline
Description: Lisofylline via i.v. administration vs Lisofylline vs s.c. administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisofylline
Description: Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
Study: NCT00733018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Western versus balanced macro nutrient diet composition
Description: Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Western versus balanced macro nutrient diet composition
Description: Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
Study: NCT00520182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MUFA diet
Description: Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids \[MUFA\]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADA 2003
Description: Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic index (LGI) diet
Description: Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
Study: NCT04504604

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FoundationOne CDx and FoundationOne Liquid CDx
Description: Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FoundationOne CDx and FoundationOne Liquid CDx
Description: Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.
Study: NCT03106597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Manidipine 20mg
Description: After a 1\~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10mg
Description: After a 1\~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period.
Study: NCT03301311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet (SCD)
Description: Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet (SCD)
Description: Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Specific Carbohydrate Diet (MSCD)
Description: Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Specific Carbohydrate Diet (MSCD)
Description: Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.